Nivestim®
Pre-clinicalTerminated 0 views this week 0 watching💤 Quiet
Interest: 18/100
18
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chemotherapy-Induced Neutropenia
Conditions
Chemotherapy-Induced Neutropenia
Trial Timeline
Sep 1, 2014 → Jan 1, 2017
NCT ID
NCT02454530About Nivestim®
Nivestim® is a pre-clinical stage product being developed by Pfizer for Chemotherapy-Induced Neutropenia. The current trial status is terminated. This product is registered under clinical trial identifier NCT02454530. Target conditions include Chemotherapy-Induced Neutropenia.
What happened to similar drugs?
3 of 20 similar drugs in Chemotherapy-Induced Neutropenia were approved
Approved (3) Terminated (4) Active (14)
🔄Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
3
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02454530 | Pre-clinical | Terminated |
| NCT01574235 | Pre-clinical | Completed |
Competing Products
20 competing products in Chemotherapy-Induced Neutropenia